Wednesday, September 3, 2014
Viking Therapeutics Sets IPO Range
San Diego-based biopharmaceuticals developer Viking Therapeutics has set the estimated pricing for its IPO, saying in a filing Tuesday that it expects to price its IPO at between $10.00 and $12.00 per share. The company has applied to list as VKTX on the NASDAQ Global market. The company is hoping to raise up to $69.0M in its offering. The IPO is being underwritten by Oppenheimer & Co., Roth Capital Partners, Craig-Hallum Capital Group, MLV & Co., and Summer Street Research Partners. The company is developing treatments for treating Type 2 diabetes and other metabolic diseases.